Roquefort Investments PLC (GB:ROQ) has released an update. Roquefort Therapeutics PLC has announced a promising interim report, highlighting a $10 million out-licensing deal for its Midkine antibody program and significant
Roquefort Investments PLC (GB:ROQ) has released an update. Roquefort Therapeutics PLC has announced a promising interim report, highlighting a $10 million out-licensing deal for its Midkine antibody program and significant
Roquefort Investments PLC (GB:ROQ) has released an update. Roquefort Therapeutics has announced the grant of a Japanese patent for its innovative MK cell therapy, expanding its intellectual property protection across
Roquefort Investments PLC (GB:ROQ) has released an update. Roquefort Therapeutics has announced promising results for its STAT-6 siRNA in treating immunological diseases, marking a significant advancement in its pre-clinical development.
Roquefort Investments PLC (GB:ROQ) has released an update. Roquefort Therapeutics has been granted a European patent for its innovative Mesodermal Killer (MK) cell therapy, applicable in 39 countries, which promises
Roquefort Investments PLC (GB:ROQ) has released an update. Roquefort Therapeutics PLC successfully held its AGM, with shareholders unanimously passing all proposed resolutions, reflecting strong support for the company’s direction. The